{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:36:43Z","timestamp":1792093003988,"version":"4.4.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ctrv.2023.102603","type":"journal-article","created":{"date-parts":[[2023,8,6]],"date-time":"2023-08-06T20:21:55Z","timestamp":1691353315000},"page":"102603","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["Expert consensus guidelines for the prophylaxis and management of tumor lysis syndrome in the United States: Results of a modified Delphi panel"],"prefix":"10.1016","volume":"120","author":[{"given":"Anthony J.","family":"Perissinotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Bubalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark B.","family":"Geyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Goodrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott C.","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julianna","family":"Kula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreedhar","family":"Mandayam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell S.","family":"Cairo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Hon","family":"Pui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2023.102603_b0005","series-title":"StatPearls [Internet]","article-title":"Tumor lysis syndrome","author":"Adeyinka","year":"2021"},{"issue":"4","key":"10.1016\/j.ctrv.2023.102603_b0010","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.1365-2141.2010.08143.x","article-title":"Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus","volume":"149","author":"Cairo","year":"2010","journal-title":"Br J Haematol"},{"issue":"16","key":"10.1016\/j.ctrv.2023.102603_b0015","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1200\/JCO.2007.15.0177","article-title":"Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review","volume":"26","author":"Coiffier","year":"2008","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.ctrv.2023.102603_b0020","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1056\/NEJMra0904569","article-title":"The tumor lysis syndrome","volume":"364","author":"Howard","year":"2011","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ctrv.2023.102603_b0025","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1093\/ndt\/gfp330","article-title":"A novel role for uric acid in acute kidney injury associated with tumour lysis syndrome","volume":"24","author":"Shimada","year":"2009","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102603_b0030","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102603_b0035","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1590\/S1807-59322009000500016","article-title":"Systemic inflammatory response syndrome and multiple organ dysfunction in patients with acute tumor lysis syndrome","volume":"64","author":"Soares","year":"2009","journal-title":"Clinics (Sao Paulo)"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102603_b0040","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2004.05094.x","article-title":"Tumour lysis syndrome: new therapeutic strategies and classification","volume":"127","author":"Cairo","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2023.102603_b0045","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): B-Cell Lymphomas, Version 1.2022\u2014March 2, 2022. 2022."},{"key":"10.1016\/j.ctrv.2023.102603_b0050","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Acute Myeloid Leukemia, Version 1.2022\u2014December 2, 2021. 2021."},{"key":"10.1016\/j.ctrv.2023.102603_b0055","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Acute Lymphoblastic Leukemia, Version 4.2021\u2014January 7, 2022. 2022."},{"key":"10.1016\/j.ctrv.2023.102603_b0060","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma, Version 2.2022\u2014January 18, 2022. 2022."},{"key":"10.1016\/j.ctrv.2023.102603_b0065","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Chronic Myeloid Leukemia, Version 3.2022\u2014January 27, 2022. 2022."},{"key":"10.1016\/j.ctrv.2023.102603_b0070","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Multiple Myeloma, Version 5.2022\u2014March 9, 2022. 2022."},{"key":"10.1016\/j.ctrv.2023.102603_b0075","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): T-cell Lymphomas, Version 2.2022\u2014March 7, 2022. 2022."},{"issue":"4","key":"10.1016\/j.ctrv.2023.102603_b0080","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bjh.15159","article-title":"The epidemiology of rasburicase use in paediatric patients with acute lymphoblastic leukaemia and non-Hodgkin lymphoma","volume":"184","author":"Citrin","year":"2019","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.ctrv.2023.102603_b0085","doi-asserted-by":"crossref","first-page":"979","DOI":"10.2105\/AJPH.74.9.979","article-title":"Consensus methods: characteristics and guidelines for use","volume":"74","author":"Fink","year":"1984","journal-title":"Am J Public Health"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102603_b0090","first-page":"655","article-title":"How to use the nominal group and Delphi techniques","volume":"38","author":"McMillan","year":"2016","journal-title":"Int J Clin Pharm"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102603_b0095","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/bjh.13403","article-title":"Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology","volume":"169","author":"Jones","year":"2015","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102603_b0100","first-page":"425","article-title":"Development of trigger tools for surveillance of adverse events in ambulatory surgery","volume":"19","author":"Kaafarani","year":"2010","journal-title":"Qual Saf Health Care"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102603_b0105","doi-asserted-by":"crossref","first-page":"9","DOI":"10.5492\/wjccm.v7.i1.9","article-title":"Adverse events in critical care: search and active detection through the Trigger Tool","volume":"7","author":"Molina","year":"2018","journal-title":"World J Crit Care Med"},{"issue":"7","key":"10.1016\/j.ctrv.2023.102603_b0110","first-page":"705","article-title":"Managing tumor lysis syndrome in the era of novel cancer therapies","volume":"8","author":"McBride","year":"2017","journal-title":"J Adv Pract Oncol"},{"key":"10.1016\/j.ctrv.2023.102603_b0115","year":"2021","journal-title":"VENCLEXTA (venetoclax). Prescribing Information."},{"issue":"5","key":"10.1016\/j.ctrv.2023.102603_b0120","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood.2021011386","article-title":"Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome","volume":"139","author":"Davids","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102603_b0125","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102603_b0130","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00277-020-03911-z","article-title":"Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax","volume":"99","author":"Wang","year":"2020","journal-title":"Ann Hematol"},{"issue":"14","key":"10.1016\/j.ctrv.2023.102603_b0135","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.1158\/1078-0432.CCR-19-0361","article-title":"Tumor lysis, adverse events, and dose adjustments in 297 venetoclax-treated CLL patients in routine clinical practice","volume":"25","author":"Roeker","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102603_b0140","doi-asserted-by":"crossref","first-page":"E65","DOI":"10.1002\/ajh.26060","article-title":"Incidence of tumor lysis syndrome in patients with acute myeloid leukemia undergoing low-intensity induction with venetoclax","volume":"96","author":"Diao","year":"2021","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.ctrv.2023.102603_b0145","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ctrv.2023.102603_b0150","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S1470-2045(20)30060-7","article-title":"Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study","volume":"21","author":"Karol","year":"2020","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2023.102603_b0155","first-page":"5323","article-title":"Tumor lysis syndrome risk in outpatient versus inpatient administration of venetoclax and hypomethlators for acute myeloid leukemia","volume":"29","author":"Pelcovits","year":"2021","journal-title":"Support Care Cancer"},{"issue":"22","key":"10.1016\/j.ctrv.2023.102603_b0160","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","article-title":"Ibrutinib and venetoclax for first-line treatment of CLL","volume":"380","author":"Jain","year":"2019","journal-title":"N Engl J Med"},{"issue":"34","key":"10.1016\/j.ctrv.2023.102603_b0165","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1200\/JCO.21.00807","article-title":"Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study","volume":"39","author":"Wierda","year":"2021","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.ctrv.2023.102603_b0170","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2021-147790","article-title":"Comparison of tumor lysis syndrome (TLS) risk reduction and incidence in different venetoclax-based combinations within the randomized phase 3 GAIA (CLL13) trial","volume":"138","author":"F\u00fcrstenau","year":"2021","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ctrv.2023.102603_b0175","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1182\/blood.V94.4.1209","article-title":"Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia","volume":"94","author":"D\u00f6rdelmann","year":"1999","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102603_b0180","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1159\/000210392","article-title":"Management of hyperleukocytosis and prevention of tumor lysis syndrome with low-dose prednisone continuous infusion in children with acute lymphoblastic leukemia","volume":"121","author":"Ozdemir","year":"2009","journal-title":"Acta Haematol"},{"key":"10.1016\/j.ctrv.2023.102603_b0185","series-title":"StatPearls [Internet]. Treasure Island","article-title":"Hyperkalemia","author":"Simon","year":"2022"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102603_b0190","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/joa3.12482","article-title":"Arrhythmia in tumor lysis syndrome and associated in-hospital mortality: a nationwide inpatient analysis","volume":"37","author":"Gangani","year":"2021","journal-title":"J Arrhythm"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102603_b0195","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13613-022-00990-1","article-title":"Tumor lysis syndrome, acute kidney injury and disease-free survival in critically ill patients requiring urgent chemotherapy","volume":"12","author":"Abdel-Nabey","year":"2022","journal-title":"Ann Intensive Care"},{"issue":"4","key":"10.1016\/j.ctrv.2023.102603_b0200","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/bjh.12415","article-title":"Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en R\u00e9animation Respiratoire et Onco-H\u00e9matologique","volume":"162","author":"Darmon","year":"2013","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.ctrv.2023.102603_b0205","doi-asserted-by":"crossref","first-page":"e29255","DOI":"10.1002\/pbc.29255","article-title":"Fluid overload and acute kidney injury in children with tumor lysis syndrome","volume":"68","author":"Flood","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"16","key":"10.1016\/j.ctrv.2023.102603_b0210","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1007\/s40620-022-01263-7","article-title":"Serum phosphate level and its kinetic as an early marker of acute kidney injury in tumor lysis syndrome","volume":"35","author":"Lemerle","year":"2022","journal-title":"J Nephrol"},{"key":"10.1016\/j.ctrv.2023.102603_b0215","first-page":"1298674","article-title":"Lanthanum-induced radiopaque intestinal precipitates: a potential cause of intestinal foreign bodies","volume":"2019","author":"Galo","year":"2019","journal-title":"Case Rep Nephrol"},{"key":"10.1016\/j.ctrv.2023.102603_b0220","series-title":"StatPearls [Internet]. Treasure Island","article-title":"Allopurinol","author":"Qurie","year":"2021"},{"issue":"7","key":"10.1016\/j.ctrv.2023.102603_b0225","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJM197008132830708","article-title":"Xanthine nephropathy in a patient with lymphosarcoma treated with allopurinol","volume":"283","author":"Band","year":"1970","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102603_b0230","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s00467-006-0287-z","article-title":"Acute renal failure from xanthine nephropathy during management of acute leukemia","volume":"22","author":"LaRosa","year":"2007","journal-title":"Pediatr Nephrol"},{"issue":"12","key":"10.1016\/j.ctrv.2023.102603_b0235","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1093\/clinchem\/33.12.2314","article-title":"Xanthine lithiasis, nephrocalcinosis, and renal failure in a leukemia patient treated with allopurinol","volume":"33","author":"Potter","year":"1987","journal-title":"Clin Chem"},{"issue":"4","key":"10.1016\/j.ctrv.2023.102603_b0240","first-page":"525","article-title":"Febuxostat administration for the prevention of tumour lysis syndrome: a meta-analysis","volume":"44","author":"Bellos","year":"2019","journal-title":"J Clin Pharm Ther"},{"issue":"13","key":"10.1016\/j.ctrv.2023.102603_b0245","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ctrv.2023.102603_b0250","first-page":"2273","article-title":"Postchemotherapy purine excretion in lymphoma patients receiving allopurinol","volume":"41","author":"Hande","year":"1981","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2023.102603_b0255","series-title":"StatPearls [Internet]. Treasure Island","article-title":"Hyperuricemia","author":"George","year":"2021"},{"key":"10.1016\/j.ctrv.2023.102603_b0260","unstructured":"ELITEK (rasburicase). Prescribing Information. 2019."},{"issue":"10","key":"10.1016\/j.ctrv.2023.102603_b0265","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1182\/blood.V97.10.2998","article-title":"A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis","volume":"97","author":"Goldman","year":"2001","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ctrv.2023.102603_b0270","first-page":"39","article-title":"Hyperuricemia management","volume":"5","author":"Diaz","year":"2015","journal-title":"J Hematol Oncol Pharm"},{"issue":"1","key":"10.1016\/j.ctrv.2023.102603_b0275","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/jcpt.12479","article-title":"The optimal single-dose regimen of rasburicase for management of tumour lysis syndrome in children and adults: a systematic review and meta-analysis","volume":"42","author":"Yu","year":"2017","journal-title":"J Clin Pharm Ther"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102603_b0280","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1177\/1078155216687152","article-title":"Rational use of rasburicase for the treatment and management of tumor lysis syndrome","volume":"24","author":"Shaikh","year":"2018","journal-title":"J Oncol Pharm Pract"},{"issue":"7","key":"10.1016\/j.ctrv.2023.102603_b0285","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1182\/blood-2006-07-036665","article-title":"Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents","volume":"109","author":"Cairo","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102603_b0290","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.clml.2016.11.003","article-title":"A clinical and economic comparison of rasburicase and allopurinol in the treatment of patients with clinical or laboratory tumor lysis syndrome","volume":"17","author":"Cairo","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"10.1016\/j.ctrv.2023.102603_b0295","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/bjh.12542","article-title":"Rasburicase in the prevention of laboratory\/clinical tumour lysis syndrome in children with advanced mature B-NHL: a Children's Oncology Group Report","volume":"163","author":"Galardy","year":"2013","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.ctrv.2023.102603_b0300","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1517\/14656560902781972","article-title":"A single dose of rasburicase in elderly patients with hyperuricaemia reduces serum uric acid levels and improves renal function","volume":"10","author":"Malaguarnera","year":"2009","journal-title":"Expert Opin Pharmacother"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737223000968?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737223000968?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:29:31Z","timestamp":1759656571000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737223000968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":60,"alternative-id":["S0305737223000968"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2023.102603","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expert consensus guidelines for the prophylaxis and management of tumor lysis syndrome in the United States: Results of a modified Delphi panel","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2023.102603","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102603"}}